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INTERVENTIONAL CARDIOLOGY
Cost-effectiveness of PCI guided by fractional 
flow reserve
Doralisa Morrone and William S. Weintraub
In 2009, the FAME investigators reported that percutaneous coronary intervention guided by fractional !ow 
reserve (FFR) could reduce the incidence of cardiovascular events when compared with angiographically guided 
PCI. The economic study conducted on the basis of FAME has now shown that an FFR-guided approach can also 
result in reduced costs.
Morrone, D. & Weintraub, W. S. Nat. Rev. Cardiol. 8, 125–126 (2011); doi:10.1038/nrcardio.2011.10
Coronary revascularization strategies have 
been evaluated in numerous clinical trials. 
As coronary revascularization has become 
more common, concerns over financial costs 
have increased.1 Studies of the costs involved 
in revascularization therapy, including 
cost-effectiveness analysis, have been con-
ducted alongside clinical trials for 30 years. 
William F. Fearon and his co- investigators in 
the Fractional Flow Reserve versus Angio-
graphy for Multivessel Evaluation (FAME) 
trial2 have now reported that a strateg y of 
fractional flow reserve (FFR) guidance is a 
cost-effective alternative to angiographic 
guidance of percutaneous coronary inter-
vention (PCI), with overall costs at 1 year of 
US$14,315 in the FFR group versus $16,700 
in the angiography group.3
FAME is an important randomized, multi-
center trial comparing outcomes of PCI 
using either angiographic guidance alone or 
angiographic guidance plus fractional flow 
reserve (FFR) guidance to select lesions for 
intervention.2 FFR is used to assess the pres-
sure differences across a coronary stenosis 
by measuring the pressure in the coronary 
artery proximal and distal to the stenosis. In 
the FFR-guided arm of FAME, lesions with 
a substantial pressure drop were targeted, 
whereas those without a pressure drop were 
not. In the angiographic arm, the coronary 
arteriogram was used to guide revasculari-
zation. The primary end point in FAME was 
a composite of major cardiac events, which 
included death, myocardial infarction, 
and repeat revascularization at 1 year. The 
primary end point occurred in significantly 
fewer of the patients in the FFR-guidance 
group than in the angiographic-guidance 
group (13.2% versus 18.3%, P = 0.02).2
On the basis of FAME, Fearon et al. have 
now conducted a prospective economic 
evalu ation of FFR-guided PCI compared with 
angiographically guided PCI.3 The FAME 
economic study was a stochastic analy sis in 
which patient-level data on costs and effects 
were used, as opposed to an analysis based 
on averages of composite data from the 
liter ature. Microcosting was used to assess 
the costs of the initial hospitali zation, using 
US site-cost weights for specific resources, 
such as stents. Subsequent cardiovascular 
hospitali zation costs were calculated on the 
basis of Medicare reimbursement rates by 
diagnosis-related group. Outpatient costs 
and indirect costs were not assessed.
Quality-adjusted life years (QALYs) were 
calculated by multiplying survival by utility, 
which was assessed using responses to 
the EQ-5D® (Stichting EuroQol Group, 
Dordrecht, The Netherlands) questionnaire 
collected at baseline, after 1 month, and at 
1 year. QALYs at 1 year after randomi zation 
tended to be greater in the FFR arm (0.853 
versus 0.838, P = 0.20) than in the angio-
graphy arm. Costs of the index procedure, 
hospitalization, repeat PCI, and CABG 
surgery, as well as costs associated with myo-
cardial infarction (MI) and MI with PCI 
were lower in the FFR arm ($14,315 versus 
$16,700, P <0.0001). The confidence inter-
vals for differences in QALYs and costs 
between the two arms were estimated using 
bootstrap analysis, which showed that FFR 
was cost-saving in 90.74% bootstrap repli-
cations. Moreover, in 99.96% of simula-
tions, the incremental cost-effectiveness 
ratio was below the commonly used societal 
willingness-to-pay threshold of $50,000. 
In addition to bootstrap analysis, sensiti-
vity analysis indicated that the results were 
robust within reasonable limits of parameter 
values. Thus, Fearon et al. found FFR-guided 
therapy to be the appro priate approach com-
pared with angiographic guidance, offer-
ing both improved patient outcomes and 
saving money.3
The FAME cost-effectiveness analysis 
follows a long history of economic studies 
conducted alongside trials of revasculari-
zation strategies. In the Emory Angioplasty 
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‘‘FAME is ... unusual in finding that FFR guidance resulted in 
improved outcomes at lower 
cost’’
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versus Surgical Trial (EAST),4 percutaneous 
transluminal coronary angioplasty (PTCA) 
was compared with CABG surgery. Fewer 
patients in the surgery group than in the 
angioplasty group reported angina (12% 
versus 20%, P = 0.039) at 3 years follow-up. 
Although initial hospital costs and profes-
sional fees were lower in the angioplasty 
group, this difference disappeared by 8 years 
of follow-up.5
In the Randomized Intervention Treat-
ment of Angina (RITA) economic evalu-
ation,6 in which PTCA was compared with 
CABG surgery, the prevalence of angina 
during follow-up was greater in the PTCA 
group and antianginal drugs were prescribed 
more frequently to patients undergoing 
PTCA. Although initial hospital costs were 
lower in the PTCA arm, again, this difference 
disappeared at 5 years of follow-up.6
In 2007, the results of the Clinical outcomes 
Utilizing Revascularization and aggres-
sive DruG Evaluation (COURAGE) trial7 
showed that PCI in addition to medical 
therapy did not reduce risk of death or 
MI when compared with medical therapy 
alone, although an improvement in symp-
toms was reported with PCI for a period 
of between 1 and 3 years. Results from the 
COURAGE cost-effectiveness analysis were 
published in 2008 and showed that PCI 
plus medical therapy was more expensive 
than medi cal therapy alone.8
Studies of coronary revascularization 
strategie s have generally shown that the 
therapy offering the better outcome does so at 
in creased cost. FAME is, therefore, relatively 
unusual in finding that FFR guidance resulted 
in improved outcomes at lower cost when 
compared with angiographic guidance. 
Some limitations of this study should be 
noted. The first is that the time horizon was 
limited to 1 year. A lifetime analysis would 
be likely to reveal increased costs associated 
with FFR guidance compared with angio-
graphic guidance owing to prolongation of 
life. Thus, a lifetime study might show in the 
future that FFR should not be a dominant 
strategy. The cost analysis was also limited 
in that outpatient services, outpatient medi-
cations, and noncardiac hospitali zations 
were not included. In addition, the methods 
of costing the initial hospitalization were 
dependent on microcosting in just one 
center in the USA. Furthermore, the differ-
ence in QALYs between the two arms of the 
study was small and did not reach statistical 
significance. Finally, FAME was a fairly small 
study with just 1,005 patients, and has not yet 
been replicated.
FAME and its associated economic study 
are of great interest. Application of an FFR-
guided approach to PCI has increased in 
the past couple of years, in part because of the 
publication of the results from FAME. FFR 
guidance for PCI in patients with lesions of 
uncertain severity now has a class IIa recom-
mendation in the ACC/AHA guidelines9 and 
a class Ia recommendation in the European 
Society of Cardiology guidelines.10 However, 
to what extent the results of FAME can be 
generalized, and just how widely an FFR-
guided approach to PCI should be applied 
awaits further study.
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ATRIAL FIBRILLATION
Therapy with omega-3 fatty 
acids—is the case closed?
Stanley Nattel and David R. Van Wagoner
Omega-3 fatty acids have anti-in!ammatory, antioxidant and membrane-
stabilizing properties that indicate they could be useful in suppressing 
cardiac rhythm disorders. These natural dietary constituents are of 
particular interest for the treatment of atrial "brillation, a common and 
problematic cardiac arrhythmia. However, a new, well-designed clinical 
study has raised major questions about their value for this indication.
Nattel, S. & Van Wagoner, D. R. Nat. Rev. Cardiol. 8, 126–128 (2011); doi:10.1038/nrcardio.2011.11
Atrial fibrillation (AF) is a very common 
arrhythmia, and its therapy remains a chal-
lenge. Presently available drug therapy 
is inadequate and great interest exists in 
develop ing improved therapeutic approaches 
for this indication.1 Extensive evidence 
points to potentially beneficial effects of fish 
oils, in particular omega-3 polyunsaturated 
fatty acids (PUFAs), on AF.2 Since PUFAs are 
a natural dietary constituent and have very 
few adverse effects, any efficacy of PUFAs 
against AF would be likely to translate into 
important clinical applications. Although 
many observational and unblinded studies 
point to the value of PUFAs in treating AF, 
few rigo rous randomized double-blind 
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